Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE study.

医学 佐剂 免疫疗法 癌症 化疗 肿瘤科 内科学 辅助化疗 乳腺癌
作者
Florian Lordick,M. Mauer,Gertraud Stocker,C.A. Cella,Irit Ben‐Aharon,Guillaume Piessen,L. Wyrwicz,Ghazwan Al-Haidari,Tania Fleitas,Valérie Boige,Radka Obermannová,Ute Martens,Carlos Gómez-Martín,Peter Thuss‐Patience,Virginia Arrazubi,Antonio Avallone,Kai‐Keen Shiu,P Artru,Baruch Brenner,C. Bugés Sánchez
出处
期刊:Annals of Oncology [Elsevier BV]
被引量:3
标识
DOI:10.1016/j.annonc.2024.10.829
摘要

Patients with gastro-oesophageal adenocarcinoma with tumour-positive lymph nodes (ypN+) or positive surgical margins (R1) following neoadjuvant chemotherapy and resection are at high risk of recurrence. Adjuvant nivolumab is effective in oesophageal/oesophagogastric junction cancer and residual pathological disease following chemoradiation and surgery. Immune checkpoint inhibition has shown efficacy in advanced gastro-oesophageal cancer. We hypothesised that nivolumab/ipilimumab would be more effective than adjuvant chemotherapy in high-risk (ypN+ and/or R1) patients with gastro-oesophageal adenocarcinoma following neoadjuvant chemotherapy and resection. VESTIGE was an academic international, multicentre, open-label, randomised phase II trial evaluating the efficacy of adjuvant nivolumab/ipilimumab versus chemotherapy in gastro-oesophageal adenocarcinoma at high risk of recurrence. Patients were randomised 1 : 1 to receive standard adjuvant chemotherapy (same regimen as neoadjuvant) or nivolumab 3 mg/kg intravenously (i.v.) every 2 weeks plus ipilimumab 1 mg/kg i.v. every 6 weeks for 1 year. Key inclusion criteria included ypN+ and/or R1 status after neoadjuvant chemotherapy plus surgery. The primary endpoint was disease-free survival in the intent-to-treat population. Secondary endpoints included overall survival, locoregional and distant failure rates, and safety according to National Cancer Institute Common Terminology Criteria for Adverse Events v5.0. The independent Data Monitoring Committee reviewed data from 189 of the planned 240 patients in June 2022 and recommended stopping recruitment due to futility. At the time of final analysis, median follow-up was 25.3 months for 195 patients (98 nivolumab/ipilimumab and 97 chemotherapy). Median disease-free survival for the nivolumab/ipilimumab group was 11.4 months [95% confidence interval (CI) 8.4-16.8 months] versus 20.8 months (95% CI 15.0-29.9 months) for the chemotherapy group, hazard ratio 1.55 (95% CI 1.07-2.25, one-sided P = 0.99). The 12-month disease-free survival rates were 47.1% and 64.0%, respectively. There were no toxicity concerns or excess early discontinuations. Nivolumab/ipilimumab did not improve disease-free survival compared with chemotherapy in patients with ypN+ and/or R1 gastro-oesophageal adenocarcinoma following neoadjuvant chemotherapy and surgery.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
JamesPei应助111采纳,获得10
1秒前
执笔完成签到,获得积分10
1秒前
手可摘星辰完成签到 ,获得积分10
2秒前
量子星尘发布了新的文献求助10
2秒前
李健应助大帅采纳,获得10
3秒前
4秒前
冷艳的火龙果完成签到,获得积分10
4秒前
不知完成签到 ,获得积分10
4秒前
Zard发布了新的文献求助10
6秒前
清仔发布了新的文献求助10
6秒前
7秒前
大地上的鱼完成签到,获得积分10
7秒前
7秒前
上官若男应助平常的路人采纳,获得10
7秒前
小花发布了新的文献求助10
8秒前
庸俗完成签到,获得积分10
9秒前
10秒前
论文顺利发布了新的文献求助10
10秒前
10秒前
砚行书完成签到,获得积分10
10秒前
CodeCraft应助Qsss采纳,获得10
10秒前
情怀应助葫芦娃采纳,获得10
11秒前
小慈爱鸡完成签到 ,获得积分10
11秒前
ttelsa完成签到,获得积分10
11秒前
年轻小之完成签到 ,获得积分10
11秒前
11秒前
snowdream发布了新的文献求助10
12秒前
xiaoying完成签到,获得积分10
12秒前
14秒前
大帅发布了新的文献求助10
14秒前
深情丸子发布了新的文献求助10
14秒前
通通真行完成签到,获得积分10
15秒前
17秒前
JamesPei应助科研通管家采纳,获得10
17秒前
科研通AI2S应助科研通管家采纳,获得10
17秒前
英姑应助科研通管家采纳,获得10
17秒前
研友_VZG7GZ应助科研通管家采纳,获得10
17秒前
脑洞疼应助科研通管家采纳,获得10
18秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038524
求助须知:如何正确求助?哪些是违规求助? 3576221
关于积分的说明 11374737
捐赠科研通 3305912
什么是DOI,文献DOI怎么找? 1819354
邀请新用户注册赠送积分活动 892688
科研通“疑难数据库(出版商)”最低求助积分说明 815048